SCHEDULE 13G/A 0001193125-22-107726 0001863769 XXXXXXXX LIVE 3 Common Stock 12/31/2024 0001563880 Trevi Therapeutics, Inc. 89532M101 195 Church Street, 16th Floor New Haven CT 06510 Rule 13d-1(c) Frazier Life Sciences Public Fund, L.P. DE 0.00 8819620.00 0.00 8819620.00 8819620.00 9.9 PN The shares listed in rows 6, 8 and 9 consist of 8,818,620 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. The percentage listed in row 11 is calculated based on (i) 76,865,711 shares of Common Stock outstanding on October 31, 2024, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 6, 2024, and (ii) 12,500,000 shares of Common Stock that were sold by the Issuer in connection with its public offering as described in the Issuer's final prospectus filed with the SEC pursuant to Rule 424(b)(5) on December 16, 2024. FHMLSP, L.P. DE 0.00 8819620.00 0.00 8819620.00 8819620.00 9.9 PN The shares listed in rows 6, 8 and 9 consist of 8,818,620 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. The percentage listed in row 11 is calculated based on (i) 76,865,711 shares of Common Stock outstanding on October 31, 2024, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 6, 2024, and (ii) 12,500,000 shares of Common Stock that were sold by the Issuer in connection with its public offering as described in the Issuer's final prospectus filed with the SEC pursuant to Rule 424(b)(5) on December 16, 2024. FHMLSP, L.L.C. DE 0.00 8819620.00 0.00 8819620.00 8819620.00 9.9 OO The shares listed in rows 6, 8 and 9 consist of 8,818,620 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. The percentage listed in row 11 is calculated based on (i) 76,865,711 shares of Common Stock outstanding on October 31, 2024, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 6, 2024, and (ii) 12,500,000 shares of Common Stock that were sold by the Issuer in connection with its public offering as described in the Issuer's final prospectus filed with the SEC pursuant to Rule 424(b)(5) on December 16, 2024. Frazier Life Sciences X, L.P. DE 0.00 428000.00 0.00 428000.00 428000.00 0.5 PN The shares listed in rows 6, 8 and 9 consist of 428,000 shares of Common Stock held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P. The percentage listed in row 11 is calculated based on (i) 76,865,711 shares of Common Stock outstanding on October 31, 2024, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 6, 2024, and (ii) 12,500,000 shares of Common Stock that were sold by the Issuer in connection with its public offering as described in the Issuer's final prospectus filed with the SEC pursuant to Rule 424(b)(5) on December 16, 2024. FHMLS X, L.P. DE 0.00 428000.00 0.00 428000.00 428000.00 0.5 PN The shares listed in rows 6, 8 and 9 consist of 428,000 shares of Common Stock held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P. The percentage listed in row 11 is calculated based on (i) 76,865,711 shares of Common Stock outstanding on October 31, 2024, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 6, 2024, and (ii) 12,500,000 shares of Common Stock that were sold by the Issuer in connection with its public offering as described in the Issuer's final prospectus filed with the SEC pursuant to Rule 424(b)(5) on December 16, 2024. FHMLS X, L.L.C. DE 0.00 428000.00 0.00 428000.00 428000.00 0.5 OO The shares listed in rows 6, 8 and 9 consist of 428,000 shares of Common Stock held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P. The percentage listed in row 11 is calculated based on (i) 76,865,711 shares of Common Stock outstanding on October 31, 2024, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 6, 2024, and (ii) 12,500,000 shares of Common Stock that were sold by the Issuer in connection with its public offering as described in the Issuer's final prospectus filed with the SEC pursuant to Rule 424(b)(5) on December 16, 2024. Frazier Life Sciences XI, L.P. DE 0.00 1417154.00 0.00 1417154.00 1417154.00 1.6 PN The shares listed in rows 6, 8 and 9 consist of 1,417,154 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P. The percentage listed in row 11 is calculated based on (i) 76,865,711 shares of Common Stock outstanding on October 31, 2024, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 6, 2024, and (ii) 12,500,000 shares of Common Stock that were sold by the Issuer in connection with its public offering as described in the Issuer's final prospectus filed with the SEC pursuant to Rule 424(b)(5) on December 16, 2024. FHMLS XI, L.P. DE 0.00 1417154.00 0.00 1417154.00 1417154.00 1.6 PN The shares listed in rows 6, 8 and 9 consist of 1,417,154 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P. The percentage listed in row 11 is calculated based on (i) 76,865,711 shares of Common Stock outstanding on October 31, 2024, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 6, 2024, and (ii) 12,500,000 shares of Common Stock that were sold by the Issuer in connection with its public offering as described in the Issuer's final prospectus filed with the SEC pursuant to Rule 424(b)(5) on December 16, 2024. FHMLS XI, L.L.C. DE 0.00 1417154.00 0.00 1417154.00 1417154.00 1.6 OO The shares listed in rows 6, 8 and 9 consist of 1,417,154 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P. The percentage listed in row 11 is calculated based on (i) 76,865,711 shares of Common Stock outstanding on October 31, 2024, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 6, 2024, and (ii) 12,500,000 shares of Common Stock that were sold by the Issuer in connection with its public offering as described in the Issuer's final prospectus filed with the SEC pursuant to Rule 424(b)(5) on December 16, 2024. James N. Topper b X1 0.00 10664774.00 0.00 10664774.00 10664774.00 11.9 IN The shares listed in rows 6, 8 and 9 consist of (i) 8,819,620 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P., (ii) 428,000 shares of Common Stock held directly by Frazier Life Sciences X, L.P., and (iii) 1,417,154 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P. The percentage listed in row 11 is calculated based on (i) 76,865,711 shares of Common Stock outstanding on October 31, 2024, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 6, 2024, and (ii) 12,500,000 shares of Common Stock that were sold by the Issuer in connection with its public offering as described in the Issuer's final prospectus filed with the SEC pursuant to Rule 424(b)(5) on December 16, 2024. Patrick J. Heron X1 0.00 10664774.00 0.00 10664774.00 10664774.00 11.9 IN The shares listed in rows 6, 8 and 9 consist of (i) 8,819,620 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P., (ii) 428,000 shares of Common Stock held directly by Frazier Life Sciences X, L.P., and (iii) 1,417,154 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P. The percentage listed in row 11 is calculated based on (i) 76,865,711 shares of Common Stock outstanding on October 31, 2024, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 6, 2024, and (ii) 12,500,000 shares of Common Stock that were sold by the Issuer in connection with its public offering as described in the Issuer's final prospectus filed with the SEC pursuant to Rule 424(b)(5) on December 16, 2024. Albert Cha X1 0.00 8819620.00 0.00 8819620.00 8819620.00 9.9 IN The shares listed in rows 6, 8 and 9 consist of 8,818,620 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. The percentage listed in row 11 is calculated based on (i) 76,865,711 shares of Common Stock outstanding on October 31, 2024, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 6, 2024, and (ii) 12,500,000 shares of Common Stock that were sold by the Issuer in connection with its public offering as described in the Issuer's final prospectus filed with the SEC pursuant to Rule 424(b)(5) on December 16, 2024. James Brush X1 0.00 8819620.00 0.00 8819620.00 8819620.00 9.9 IN The shares listed in rows 6, 8 and 9 consist of 8,818,620 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. The percentage listed in row 11 is calculated based on (i) 76,865,711 shares of Common Stock outstanding on October 31, 2024, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 6, 2024, and (ii) 12,500,000 shares of Common Stock that were sold by the Issuer in connection with its public offering as described in the Issuer's final prospectus filed with the SEC pursuant to Rule 424(b)(5) on December 16, 2024. Daniel Estes X1 0.00 1417154.00 0.00 1417154.00 1417154.00 1.6 IN The shares listed in rows 6, 8 and 9 consist of 1,417,154 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P. The percentage listed in row 11 is calculated based on (i) 76,865,711 shares of Common Stock outstanding on October 31, 2024, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 6, 2024, and (ii) 12,500,000 shares of Common Stock that were sold by the Issuer in connection with its public offering as described in the Issuer's final prospectus filed with the SEC pursuant to Rule 424(b)(5) on December 16, 2024. Trevi Therapeutics, Inc. 195 Church Street, 16th Floor, New Haven, CT, 06510. The entities and persons filing this statement (collectively, the "Reporting Persons") are: Frazier Life Sciences Public Fund, L.P. ("FLSPF") FHMLSP, L.P. FHMLSP, L.L.C. Frazier Life Sciences XI, L.P. ("FLS XI") FHMLS XI, L.P. FHMLS XI, L.L.C. Frazier Life Sciences X, L.P. ("FLS X") FHMLS X, L.P. FHMLS X, L.L.C. James N. Topper ("Topper") Patrick J. Heron ("Heron") Albert Cha ("Cha") James Brush ("Brush") Daniel Estes ("Estes" and together with Topper, Heron, Cha and Brush, the "Members") The address and principal business office of the Reporting Persons is: c/o Frazier Life Sciences Management, L.P. 1001 Page Mill Rd, Building 4, Suite B Palo Alto, CA 94304 Entities: FLSPF - Delaware, U.S.A. FHMLSP, L.P. - Delaware, U.S.A. FHMLSP, L.L.C. - Delaware, U.S.A. FLS XI - Delaware, U.S.A. FHMLS XI, L.P. - Delaware, U.S.A. FHMLS XI, L.L.C. - Delaware, U.S.A. FLS X - Delaware, U.S.A. FHMLS X, L.P. - Delaware, U.S.A. FHMLS X, L.L.C. - Delaware, U.S.A. Individuals: Topper - United States Citizen Heron - United States Citizen Cha - United States Citizen Brush - United States Citizen Estes - United States Citizen Y The information contained in row 9 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference. The information contained in row 11 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference. The information contained in row 5 of each Reporting Person's cover page to this Schedule 13G is incorporated by reference. The information contained in row 6 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference. The information contained in row 7 of each Reporting Person's cover page to this Schedule 13G is incorporated by reference. The information contained in row 8 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference. Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Exhibit 99.1 Joint Filing Agreement Frazier Life Sciences Public Fund, L.P. /s/ Steve R. Bailey 02/14/2025 FHMLSP, L.P. /s/ Steve R. Bailey 02/14/2025 FHMLSP, L.L.C. /s/ Steve R. Bailey 02/14/2025 Frazier Life Sciences X, L.P. /s/ Steve R. Bailey 02/14/2025 FHMLS X, L.P. /s/ Steve R. Bailey 02/14/2025 FHMLS X, L.L.C. /s/ Steve R. Bailey 02/14/2025 Frazier Life Sciences XI, L.P. /s/ Steve R. Bailey 02/14/2025 FHMLS XI, L.P. /s/ Steve R. Bailey 02/14/2025 FHMLS XI, L.L.C. /s/ Steve R. Bailey 02/14/2025 James N. Topper /s/ Steve R. Bailey 02/14/2025 Patrick J. Heron /s/ Steve R. Bailey 02/14/2025 Albert Cha /s/ Steve R. Bailey 02/14/2025 James Brush /s/ Steve R. Bailey 02/14/2025 Daniel Estes /s/ Steve R. Bailey 02/14/2025